{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:48:49Z","timestamp":1777265329541,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cardiovascular prevention has traditionally focused on achieving progressively lower low-density lipoprotein cholesterol (LDL-C) targets, particularly in individuals classified as high risk. However, accumulating evidence from epidemiological, genetic and clinical studies suggests that cardiovascular risk is strongly influenced by cumulative lifetime exposure to LDL-C rather than by isolated LDL-C levels achieved later in life. From an endocrine perspective, LDL-C should be viewed as a chronic metabolic exposure whose pathogenic impact depends not only on its intensity, but also on its duration over time. This Perspective integrates evidence from longitudinal cohort studies, familial hypercholesterolaemia and Mendelian randomisation analyses, and contrasts current lipid management paradigms with preventive strategies routinely applied to other endocrine\u2013metabolic disorders. While contemporary guidelines recognise the causal role of LDL-C and increasingly acknowledge lifetime risk, this recognition is not always fully translated into operational criteria for early intervention, particularly in younger adults. Within this context, earlier approaches aimed at limiting cumulative LDL-C exposure may offer additional long-term benefit, especially in individuals with long life expectancy. This Perspective, grounded in an endocrine framework, is intended to complement, rather than replace, current guideline-based strategies by highlighting the potential value of incorporating cumulative exposure into preventive decision-making.<\/jats:p>","DOI":"10.3389\/fendo.2026.1813342","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:23Z","timestamp":1777264103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Why does LDL-C follow a different paradigm from other endocrine\u2013metabolic diseases in cardiovascular prevention?"],"prefix":"10.3389","volume":"17","author":[{"given":"Jos\u00e9 Luis","family":"S\u00e1nchez-Quesada","sequence":"first","affiliation":[{"name":"Cardiovascular Biochemistry, Institut de Recerca Sant Pau (IR Sant Pau)","place":["Barcelona, Spain"]},{"name":"CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM)","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM)","place":["Barcelona, Spain"]},{"name":"Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]},{"name":"Facultat de Medicina, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35)","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC guideline on the management of blood cholesterol","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B11","article-title":"Cardiovascular disease: risk assessment and lipid modification. NICE guideline [NG238]","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of Dyslipidemia and Prevention of Cardiovascular Disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: Endocrine Society guideline","volume":"105","author":"Handelsman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative LDL cholesterol exposure and cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower LDL cholesterol beginning early in life","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease","volume":"374","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.3.331","article-title":"Statin therapy in children with familial hypercholesterolaemia","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolaemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031855","article-title":"Quantifying importance of major risk factors for coronary heart disease","volume":"139","author":"Pencina","year":"2019","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40273-023-01306-2","article-title":"Lipid-lowering strategies for primary prevention of coronary heart disease in the UK: A cost-effectiveness analysis","volume":"42","author":"Morton","year":"2024","journal-title":"PharmacoEconomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of LDL cholesterol with cardiovascular mortality in low-risk individuals","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"500894","DOI":"10.1016\/j.arteri.2026.500894","article-title":"Lipid prevention in type 1 diabetes: from estimated risk to cumulative risk","author":"Mi\u00f1ambres","year":"2026","journal-title":"Clin Investig Arterioscler"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1813342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:24Z","timestamp":1777264104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1813342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":24,"alternative-id":["10.3389\/fendo.2026.1813342"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1813342","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1813342"}}